1. Home
  2. Global Antimicrobial Resistance Innovation Fund (GAMRIF) - UK-China: Innovation and Collaboration to tackle AMR
UK - Department of Health and Social Care (DHSC)

Global Antimicrobial Resistance Innovation Fund (GAMRIF) - UK-China: Innovation and Collaboration to tackle AMR

Last updated: 31/08/2022
IATI Identifier: GB-GOV-10-GAMRIF-WP1-UK-CHINA
Project disclaimer
Disclaimer: The data for this page has been produced from IATI data published by UK - Department of Health and Social Care (DHSC).

Description

The UK Department of Health and Social Care (DHSC)'s UK-China research competition supports new innovations to address anti-microbial resistance (AMR) in both humans and animals, which together constitute a significant threat to human health. Successful projects are a partnership of UK companies and research organisations, with Chinese companies and research organisations. £10 million of UK aid funding has now been awarded to UK partners through delivery partner Innovate UK, with the Chinese Ministry of Science and Technology (MoST) providing funding for the Chinese partners who will receive up to a total of 60 million RMB. The output of these partnerships will benefit people in other low- and middle-income countries (LMICs) around the world.

The aim of this partnership is to support novel research projects that will develop the use of cutting edge solutions to tackle critical issues of AMR in humans and animals and other LMICs. This includes solutions that will: - explore opprtunities from Traditional Chinese Medicine for the treatment and/or prevention of infectious diseases in humans and animals - advance the discovery of new agents, incdluing small molecule drugs, vaccines, antibodies and other biological products - identify new agents that increase feed energy conversion in livestock without using antibiotics or hormones - use modelling and clinical studies to maxmise the clinical utility of current antibiotics - improve diagnostic capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.


Location

The country, countries or regions that benefit from this Programme.
Developing countries, unspecified
Disclaimer: Country borders do not necessarily reflect the UK Government's official position.

Status Implementation

The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.

Programme Spend

Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.

Participating Organisation(s)

Help with participating organisations

Accountable:Organisation responsible for oversight of the activity

Extending: Organisation that manages the budget on behalf of the funding organisation.

Funding: Organisation which provides funds.

Implementing: Organisations implementing the activity.

Sectors

Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.

Budget

A comparison across financial years of forecast budget and spend to date on the Programme.

Download IATI Data for GB-GOV-10-GAMRIF-WP1-UK-CHINA

Programme data last updated on 31/08/2022